Complex Dichotomous Links of Nonalcoholic Fatty Liver Disease and Inflammatory Bowel Disease: Exploring Risks, Mechanisms, and Management Modalities

Overview

Journal Intest Res

Date 2024 Jun 5

PMID 38835139

Authors

Kanishk Aggarwal

Bhupinder Singh

Abhishek Goel

Durgesh Kumar Agrawal

Sourav Bansal

Sai Gautham Kanagala

Fnu Anamika

Aachal Gupta

Rohit Jain

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) has been shown to be linked to inflammatory bowel disease (IBD) due to established risk factors such as obesity, age, and type 2 diabetes in numerous studies. However, alternative research suggests that factors related to IBD, such as disease activity, duration, and drug-induced toxicity, can contribute to NAFLD. Recent research findings suggest IBD relapses are correlated with dysbiosis, mucosal damage, and an increase in cytokines. In contrast, remission periods are characterized by reduced metabolic risk factors. There is a dichotomy evident in the associations between NAFLD and IBD during relapses and remissions. This warrants a nuanced understanding of the diverse influences on disease manifestation and progression. It is possible to provide a holistic approach to care for patients with IBD by emphasizing the interdependence between metabolic and inflammatory disorders.

Citing Articles

Elucidating the association between nonalcoholic fatty liver disease and incidence of inflammatory bowel disease: a focus on systemic inflammation.

Kim S, Im J Intest Res. 2025; 23(1):3-5.

PMID: 39916480 PMC: 11834359. DOI: 10.5217/ir.2024.00204.

References

Wijarnpreecha K, Kim D, Raymond P, Scribani M, Ahmed A . Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. Eur J Gastroenterol Hepatol. 2019; 31(9):1121-1128. DOI: 10.1097/MEG.0000000000001397. View

Foulds C, Trevino L, York B, Walker C . Endocrine-disrupting chemicals and fatty liver disease. Nat Rev Endocrinol. 2017; 13(8):445-457. PMC: 5657429. DOI: 10.1038/nrendo.2017.42. View

Long S, Gahan C, Joyce S . Interactions between gut bacteria and bile in health and disease. Mol Aspects Med. 2017; 56:54-65. DOI: 10.1016/j.mam.2017.06.002. View

Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T . Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clin Gastroenterol Hepatol. 2021; 20(3):e573-e582. DOI: 10.1016/j.cgh.2021.02.030. View

Barrington W, Wulfridge P, Wells A, Mantilla Rojas C, Howe S, Perry A . Improving Metabolic Health Through Precision Dietetics in Mice. Genetics. 2017; 208(1):399-417. PMC: 5753872. DOI: 10.1534/genetics.117.300536. View

Jeon S . Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016; 48(7):e245. PMC: 4973318. DOI: 10.1038/emm.2016.81. View

Wang Y, Viscarra J, Kim S, Sul H . Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol. 2015; 16(11):678-89. PMC: 4884795. DOI: 10.1038/nrm4074. View

Chiang J . Bile acid metabolism and signaling. Compr Physiol. 2013; 3(3):1191-212. PMC: 4422175. DOI: 10.1002/cphy.c120023. View

Mazidi M, Katsiki N, Mikhailidis D, Banach M . Adiposity May Moderate the Link Between Choline Intake and Non-alcoholic Fatty Liver Disease. J Am Coll Nutr. 2019; 38(7):633-639. DOI: 10.1080/07315724.2018.1507011. View

10.

Sartini A, Gitto S, Bianchini M, Verga M, Di Girolamo M, Bertani A . Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. Cell Death Dis. 2018; 9(2):87. PMC: 5833704. DOI: 10.1038/s41419-017-0124-2. View

11.

Boursier J, Guillaume M, Bouzbib C, Lannes A, Pais R, Smatti S . Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2021; 46(1):101769. DOI: 10.1016/j.clinre.2021.101769. View

12.

Salehidoost R, Korbonits M . Glucose and lipid metabolism abnormalities in Cushing's syndrome. J Neuroendocrinol. 2022; 34(8):e13143. DOI: 10.1111/jne.13143. View

13.

Martinez-Dominguez S, Garcia-Mateo S, Laredo V, Gargallo-Puyuelo C, Gallego Llera B, Lopez de la Cruz J . Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review. Cancers (Basel). 2023; 15(13). PMC: 10340150. DOI: 10.3390/cancers15133367. View

14.

Ni Y, Qian L, Siliceo S, Long X, Nychas E, Liu Y . Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations. Cell Metab. 2023; 35(9):1530-1547.e8. DOI: 10.1016/j.cmet.2023.08.002. View

15.

Sid V, Siow Y, O K . Role of folate in nonalcoholic fatty liver disease. Can J Physiol Pharmacol. 2017; 95(10):1141-1148. DOI: 10.1139/cjpp-2016-0681. View

16.

Yilmaz Y, Ulukaya E, Atug O, Dolar E . Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. Eur J Gastroenterol Hepatol. 2009; 21(11):1247-51. DOI: 10.1097/MEG.0b013e32832b77ae. View

17.

Cobbina E, Akhlaghi F . Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017; 49(2):197-211. PMC: 5576152. DOI: 10.1080/03602532.2017.1293683. View

18.

Grau T, Bonet A, Rubio M, Mateo D, Farre M, Acosta J . Liver dysfunction associated with artificial nutrition in critically ill patients. Crit Care. 2007; 11(1):R10. PMC: 2147066. DOI: 10.1186/cc5670. View

19.

Barnes E, Loftus Jr E, Kappelman M . Effects of Race and Ethnicity on Diagnosis and Management of Inflammatory Bowel Diseases. Gastroenterology. 2020; 160(3):677-689. DOI: 10.1053/j.gastro.2020.08.064. View

20.

Wu P, Jia F, Zhang B, Zhang P . Risk of cardiovascular disease in inflammatory bowel disease. Exp Ther Med. 2017; 13(2):395-400. PMC: 5348671. DOI: 10.3892/etm.2016.3966. View